JPS6236501B2 - - Google Patents

Info

Publication number: JPS6236501B2
Authority: JP; Japan
Prior art keywords: ricin; effect; solution; cancer; immune
Prior art date: 1979-11-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP54144327A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5668615A (en

Inventor

Hiroshi Shionoya

Masae Arai

Nozomi Koyanagi

Hitoshi Takeuchi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-11-09

Filing date

1979-11-09

Publication date

1987-08-07

1979-11-09 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1979-11-09 Priority to JP14432779A priority Critical patent/JPS5668615A/ja

1980-11-06 Priority to DE8080106852T priority patent/DE3071651D1/de

1980-11-06 Priority to EP80106852A priority patent/EP0028815B1/de

1980-11-07 Priority to FR8023803A priority patent/FR2469711A1/fr

1980-11-07 Priority to IT25834/80A priority patent/IT1134188B/it

1981-06-09 Publication of JPS5668615A publication Critical patent/JPS5668615A/ja

1982-06-17 Priority to US06/389,456 priority patent/US4459287A/en

1987-08-07 Publication of JPS6236501B2 publication Critical patent/JPS6236501B2/ja

Status Granted legal-status Critical Current

Links

108010039491 Ricin Proteins 0.000 claims description 23
239000003623 enhancer Substances 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 description 11
230000000694 effects Effects 0.000 description 9
201000011510 cancer Diseases 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
239000004472 Lysine Substances 0.000 description 7
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
239000002504 physiological saline solution Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
241000700605 Viruses Species 0.000 description 4
229940022399 cancer vaccine Drugs 0.000 description 4
238000009566 cancer vaccine Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000003708 ampul Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 2
101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000002766 immunoenhancing effect Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000221017 Euphorbiaceae Species 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
208000018655 severe necrosis Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Botany (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP14432779A 1979-11-09 1979-11-09 Ricin-containing agent for immunological enhancement Granted JPS5668615A (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
JP14432779A JPS5668615A (en)	1979-11-09	1979-11-09	Ricin-containing agent for immunological enhancement
DE8080106852T DE3071651D1 (en)	1979-11-09	1980-11-06	The use of ricin and a pharmaceutical composition containing the same for increasing the immune response
EP80106852A EP0028815B1 (de)	1979-11-09	1980-11-06	Verwendung von Ricin und ein dieses enthaltendes Präparat zur Verstärkung der Immunreaktion
FR8023803A FR2469711A1 (fr)	1979-11-09	1980-11-07	Immunopotentialisateur contenant de la ricine et composition therapeutique le contenant
IT25834/80A IT1134188B (it)	1979-11-09	1980-11-07	Immonopotenziatore contenente ricino
US06/389,456 US4459287A (en)	1979-11-09	1982-06-17	Immunopotentiator containing recin

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP14432779A JPS5668615A (en)	1979-11-09	1979-11-09	Ricin-containing agent for immunological enhancement

Publications (2)

Publication Number	Publication Date
JPS5668615A JPS5668615A (en)	1981-06-09
JPS6236501B2 true JPS6236501B2 (de)	1987-08-07

Family

ID=15359522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP14432779A Granted JPS5668615A (en)	1979-11-09	1979-11-09	Ricin-containing agent for immunological enhancement

Country Status (6)

Country	Link
US (1)	US4459287A (de)
EP (1)	EP0028815B1 (de)
JP (1)	JPS5668615A (de)
DE (1)	DE3071651D1 (de)
FR (1)	FR2469711A1 (de)
IT (1)	IT1134188B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57197223A (en) *	1981-05-27	1982-12-03	Eisai Co Ltd	Immunoenhancing agent containing ricin b chain
JPS61165334A (ja) *	1984-08-03	1986-07-26	メデイサ−チ、エス、ア−	ウイルスの感染活性の抑制方法および組成物
JPH0825890B2 (ja) *	1987-06-18	1996-03-13	呉羽化学工業株式会社	抗ウイルス剤
KR950009099B1 (ko) *	1992-06-23	1995-08-14	한영복	항후천성면역결핍증바이러스효과를갖는생약추출조성물및그추출방법
US5453271A (en) *	1993-06-28	1995-09-26	The United States Of America As Represented By The Secretary Of The Army	Vaccine against ricin toxin
US5667786A (en) *	1995-06-07	1997-09-16	Novavax, Inc.	Method for treating tumors with a toxin
EP2361635A3 (de) *	2000-08-30	2011-09-14	Pfizer Products Inc.	Anti-IgE Vakzine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3060165A (en) *		1962-10-23		Preparation of toxic ricin
GB1522600A (en) *	1975-12-01	1978-08-23	Boehringer Sohn Ingelheim	Proteins
JPS5344613A (en) *	1976-09-30	1978-04-21	Eisai Co Ltd	Tumor vaccine containing lectin/tumor cell-complex

1979
- 1979-11-09 JP JP14432779A patent/JPS5668615A/ja active Granted
1980
- 1980-11-06 DE DE8080106852T patent/DE3071651D1/de not_active Expired
- 1980-11-06 EP EP80106852A patent/EP0028815B1/de not_active Expired
- 1980-11-07 FR FR8023803A patent/FR2469711A1/fr active Granted
- 1980-11-07 IT IT25834/80A patent/IT1134188B/it active
1982
- 1982-06-17 US US06/389,456 patent/US4459287A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0028815A3 (en)	1982-03-10
US4459287A (en)	1984-07-10
EP0028815A2 (de)	1981-05-20
EP0028815B1 (de)	1986-06-18
IT8025834A0 (it)	1980-11-07
FR2469711A1 (fr)	1981-05-22
FR2469711B1 (de)	1984-10-19
JPS5668615A (en)	1981-06-09
DE3071651D1 (en)	1986-07-24
IT1134188B (it)	1986-07-31

Publication	Publication Date	Title
US5965144A (en)	1999-10-12	Chitosan induced immunopotentiation
EP1333858B1 (de)	2006-02-08	Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
HU229968B1 (hu)	2015-03-30	Sztreptokokkusz oltóanyag
US5912000A (en)	1999-06-15	Chitosan induced immunopotentiation
Phillips et al.	1996	Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens
JPH04506662A (ja)	1992-11-19	接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
EP1259259B1 (de)	2011-06-08	Adjuvansformulierung zur scheimhaut-applikation
EP0789590B1 (de)	2002-09-04	Chitosan induzierte verstärkung
Relyveld et al.	1983	[3] Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells
JPS6236501B2 (de)	1987-08-07
JPH05504756A (ja)	1993-07-22	免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
EP2929894B1 (de)	2018-02-21	Impfungsadjuvans, herstellung und impfstoffe damit
KR20200053644A (ko)	2020-05-18	보강제 제형 및 방법
JPS6338971B2 (de)	1988-08-03
JPS6236500B2 (de)	1987-08-07
US20040081686A1 (en)	2004-04-29	Use of particle vectors in immunomodulation
CN115501333A (zh)	2022-12-23	一种疫苗佐剂、疫苗组合物及其应用
CA2255867C (en)	2008-02-05	Chitosan induced immunopotentiation
JPH11240844A (ja)	1999-09-07	肺炎球菌抗原の経口投与
JP3892165B2 (ja)	2007-03-14	百日咳ワクチン
Gizurarson et al.	1998	Intranasal vaccination: pharmaceutical evaluation of the vaccine delivery system and immunokinetic characteristics of the immune responses
JP4217418B2 (ja)	2009-02-04	キトサン誘導性免疫強化
JP2006519186A (ja)	2006-08-24	皮下投与型ガングリオシド系ワクチン組成物
JPS59205326A (ja)	1984-11-20	アブリンａ含有免疫増強剤
Akers et al.	1970	Effect of Statolon on Aerogenic Immunization of Mice with Mengovirus-37A